



Universiteit  
Leiden  
The Netherlands

## **Mechanistic early phase clinical pharmacology studies with disease-modifying drugs for neurodegenerative disorders**

Vissers, M.F.J.M.

### **Citation**

Vissers, M. F. J. M. (2023, June 21). *Mechanistic early phase clinical pharmacology studies with disease-modifying drugs for neurodegenerative disorders*. Retrieved from <https://hdl.handle.net/1887/3621076>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3621076>

**Note:** To cite this publication please use the final published version (if applicable).

## Curriculum Vitae

Maurits Frederick Johan Maria Vissers (Amsterdam, 1987) graduated from secondary school (Gymnasium, OSG Sevenwolden, Heerenveen), in 2005, and thereafter spent one year at Elizabethtown College, PA, USA as a non-degree international student. In 2006 he started studying Pharmacy at the University of Groningen and graduated *cum laude* for his master's degree in 2013. As part of his master's, he spent six months as a visiting researcher at the Massachusetts Institute of Technology, MA, USA to complete a thesis on microfluidics and organ-on-a-chip technology. At the end of his master's, he completed an internship in Pharmaceutical Manufacturing at Astellas BV, Meppel, and was asked to extend this internship as a temporary contractor Pharmaceutical Technology for three months to help resolve an antibiotic manufacturing issue. Maurits started his professional career in 2013 as a Global Project Manager Compounding and Global Management Trainee at Fagron BV, Rotterdam. In 2016 he joined the Medical Affairs department of AbbVie BV, Hoofddorp, where he worked in the field of biotherapeutics and later hepatitis C. In 2018 he was recruited for AbbVie's High Performing Leadership Program and that same year he completed a post-graduate program on Clinical Development of the Paul Janssen Future Lab, Leiden. This program sparked an enthusiasm for Clinical Development and in 2018 Maurits decided to join the Centre for Human Drug Research (CHDR, Leiden) as a Clinical Scientist and pursue a PHD in early phase clinical pharmacology studies with disease-modifying drugs for neurodegenerative disorders at Leiden University under the supervision of prof. dr. G.J. Groeneveld. During the COVID pandemic in 2020 and 2021, Maurits co-authored an ethical framework to evaluate and support the restart of clinical research at the time of the pandemic, completed research on the impact of COVID on immunosuppressant therapy pharmacokinetics in kidney transplant recipients, and led a potential COVID treatment trial in patients alongside his PHD-related trials. In 2021, Maurits transitioned to the position of Experienced Clinical Scientist and in 2022 he completed training and registered as a Clinical Pharmacologist. Since 1 January 2023, Maurits holds the position of Clinical Operations Director and has joined CHDR's Management Team. He currently lives in Amsterdam with his fiancé Mei-An Middelkoop and their two daughters Mia (2021) and Lotta (2022).

## List of Publications

**Vissers MFJM**, Cohen AF, Van Gerven JMA, Groeneveld GJ. The impact of the global COVID-19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. *Br J Clin Pharmacol.* 2021 Mar;87(3):837-844. doi: 10.1111/bcp.14480.

**Vissers MFJM**, Heuberger JAAC, Groeneveld GJ. Targeting for success: demonstrating proof-of-concept with mechanistic early phase clinical pharmacology studies for disease-modification in neurodegenerative disorders. *Int J Mol Sci.* 2021 Feb 5;22(4):1615. doi: 10.3390/ijms22041615.

Klomp SD, Meziyerh S, **Vissers MFJM**, Moes DJAR, Arends EJ, Teng YKO, Swen JJ and de Vries APJ. Increased tacrolimus exposure in kidney transplant recipients with COVID-19: inflammation-driven down-regulation of metabolism as a potential mechanism. *Transpl Int.* 2022 May 16;35:10269. doi: 10.3389/ti.2022.10269.

**Vissers MFJM**, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, Tong V, Erickson R, Zhu Y, Scearce-Levie K, Hsiao-Nakamoto J, Tang X, Chang M, Fox BM, Estrada AA, Pomponio RJ, Alonso-Alonso M, Zilberstein M, Atassi N, Troyer MD, Ho C. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase 1/1b studies in healthy subjects and patients. *Clin Transl Sci.* 2022 Aug;15(8):2010-2023. doi: 10.1111/cts.13317.

Prins MLM, van der Plas JL, **Vissers MFJM**, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC. Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19 – a phase 2a, open-label, single dose escalation study. *Br J Clin Pharmacol.* 2022 Oct 10. doi: 10.1111/bcp.15560.

Jennings D\*, Huntwork-Rodriguez S\*, **Vissers MFJM\***, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, van de Wetering de Rooij J, Heuberger JAAC, Groeneveld GJ, Borin MT, Cruz Herranz A, Graham D, Scearce-Levie K, De Vicente J, Henry AG, Chin P, Ho C, Troyer MD. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease. *Mov Disord.* 2023 Mar;38(3):386-398. doi: 10.1002/mds.29297. \*Senior authors (shared)

**Vissers MFJM**, Troyer MD, Thijssen E, Heuberger JAAC, Groeneveld GJ, Huntwork-Rodriguez S. A LRRK2 pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls. *Clin Transl Sci.* 2023 (accepted).

